Skip to main content

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Development Analysis Contributing Top Vendor Landscape and Economic Growth 2028

 


Autologous stem-cell transplantation (also known as autogeneic, autogenic, or autogenous stem-cell transplantation or auto-SCT) is the autologous transplantation of stem cells—which is, transplantation in which the undifferentiated cells or stem cells (cells from which other types of cells develop) are taken from a person, accumulated, and given back to the same person later. Even though it is most often executed by means of hematopoietic stem cells (antecedent of cells that forms blood) in hematopoietic stem cell transplantation, in some cases cardiac cells are used productively to fix the damages due to heart attacks. Stem cell transplantation can be of two types - Autologous stem-cell transplantation and allogenic stem cell transplantation. 

Increasing prevalence of cancer will drive the overall autologous stem cell and non-stem cell based therapies market

According to a report by National Cancer Institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. alone. Moreover, it was also noted that around 595,690 people died from the disease in the same year. Autologous stem cell and non-stem cell based therapies is likely to become one of the preferred treatment for cancer. As the prevalence of cancer is rising at a considerable rate, the market is likely to grow during the forecast period.

North America, followed by Europe accounted for the major share of the autologous stem cell and non-stem cell based therapies market. This is due to minimization of risks related with the treatment. Moreover, the demand for these treatments is high due to their ability to cure a significant number of infectious diseases. Autologous stem cell and non-stem cell based therapies do not need an outside donor; therefore the treatment is less infectious and convenient. These factors are likely to boost the growth of the market in North America. However, Asia Pacific is expected to show the maximum growth in the forecast period. The demand in this region will be led by countries such as China, India, Malaysia, and Vietnam. The demand is likely to grow as autologous stem cell and non-stem cell based therapies aid in the efficient management of cardiovascular diseases as well.

 

Comments

Popular posts from this blog

The Global Pressure Bandages Market Is Witnessing High Growth Owing To the Increasing Incidence of Surgical Processes in the World

  Market Overview: During a medical emergency, a pressure bandage is used to apply pressure to an area of the body to control bleeding and swelling. There are a variety of types of pressure bandages that can be used for different purposes. The bandage is made up of several parts, including an air bladder, a pad, a closure bar, and an applicator. A pressure bandage can be applied to wounds at any location on the body. This type of dressing is useful in treating various conditions, including gunshot wounds. It can also be used for a temporary holding of a hernia. The bandage is usually vacuum-sealed, so it's easier to carry. Competitive Landscape: Major players operating in the global pressure bandages market include ConvaTec Group PLC., Cardinal Health, 3M, B. Braun Melsungen AG, Lohmann & Rauscher GmbH & Co. KG, Mölnlycke Health Care AB, Smith & Nephew plc., Paul Hartmann AG, and Essity (BSN medical GmbH). Key Market Drivers: Increasing developments by key pla...

Biologics Market Increasing Prevalence of Chronic Diseases to Augment Growth of the market

  A  biologic  drug ( biologics ) is a product that is produced from living organisms or contains components of living organisms.  Biologic  drugs are widely used to prevent, diagnose, treat, or cure a variety of diseases, including infectious diseases, autoimmune disorders, chronic kidney disease, and cancer. Market Dynamics In the recent past, several novel biopharmaceutical products were approved by major regulatory bodies and major players in the market have launched various novel and innovative biopharmaceutical products. Rapid approvals and launches of novel products in the market are expected to be major drivers for growth of the biologicsmarket . 

Custom Antibody Service Market Segmentation Application, Technology and Market Analysis to 2028

  The immune system produces antibodies in response to pathogen invasion. Antigens are the collective term for the invasive bacteria, viruses, or other foreign molecules. Antibodies are proteins, or polypeptides which have specific antigen recognition sites. It is possible to have antibodies made using custom antibody production when an antibody is required against a particular antigen but it is not offered by a supplier. These antibodies can be either polyclonal or monoclonal, depending on how they are produced and harvested. Polyclonal  antibodies  are capable of recognizing multiple sites on an antigen. They are derived from different B-cell lineages. Monoclonal antibodies recognize only one epitope or site on an antigen, and are derived from a single B-cell line. Global custom antibody service market is estimated to be valued at  US$ 444.85 Million in 2022  and expected to reach  US$ 930.46 million by 2030 , witnessing a  CAGR of 9.7 %  over...